{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:43:09Z","timestamp":1792014189537,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Reddy Lee Family Moyamoya Research Fund"},{"name":"Moyamoya & Angiogenesis Research Fund"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21NS082894"],"award-info":[{"award-number":["R21NS082894"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21NS082894"],"award-info":[{"award-number":["R21NS082894"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000933","name":"William Randolph Hearst Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000933","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bernard Lacroute"},{"name":"Ronni Lacroute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl. Stroke Res."],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Moyamoya disease (MMD) is characterized by progressive occlusion of the intracranial internal carotid arteries, leading to ischemic and hemorrhagic events. Significant clinical differences exist between ischemic and hemorrhagic MMD. To understand the molecular profiles in the cerebrospinal fluid (CSF) of MMD patients, we investigated 62 secreted factors in both MMD subtypes (ischemic and hemorrhagic) and examined their relationship with preoperative perfusion status, the extent of postoperative angiographic revascularization, and functional outcomes. Intraoperative CSF was collected from 32 control and 71 MMD patients (37 ischemic and 34 hemorrhagic). Multiplex Luminex assay analysis showed that 41 molecules were significantly elevated in both MMD subtypes when compared to controls, including platelet-derived growth factor-BB (PDGF-BB), plasminogen activator inhibitor 1 (PAI-1), and intercellular adhesion molecule 1 (ICAM1) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Many of these secreted proteins have not been previously reported in MMD, including interleukins (IL-2, IL-4, IL-5, IL-7, IL-8, IL-9, IL-17, IL-18, IL-22, and IL-23) and C-X-C motif chemokines (CXCL1 and CXCL9). Pathway analysis indicated that both MMD subtypes exhibited similar cellular\/molecular functions and pathways, including cellular activation, migration, and inflammatory response. While neuroinflammation and dendritic cell pathways were activated in MMD patients, lipid signaling pathways involving nuclear receptors, peroxisome proliferator-activated receptor (PPAR), and liver X receptors (LXR)\/retinoid X receptors (RXR) signaling were inhibited. IL-13 and IL-2 were negatively correlated with preoperative cerebral perfusion status, while 7 factors were positively correlated with the extent of postoperative revascularization. These elevated cytokines, chemokines, and growth factors in CSF may contribute to the pathogenesis of MMD and represent potential future therapeutic targets.\n                  <\/jats:p>","DOI":"10.1007\/s12975-023-01135-7","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T03:03:52Z","timestamp":1675652632000},"page":"399-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comprehensive Profiling of Secreted Factors in the Cerebrospinal Fluid of Moyamoya Disease Patients"],"prefix":"10.1007","volume":"15","author":[{"given":"Kumar","family":"Abhinav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun V.","family":"Pendharkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bigder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Rosenberg-Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"1135_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archneur.1969.00480090076012","volume":"20","author":"J Suzuki","year":"1969","unstructured":"Suzuki J, Takaku A. Cerebrovascular, \u201cmoyamoya\u201d disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20:288\u201399.","journal-title":"Arch Neurol"},{"key":"1135_CR2","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1056\/NEJMra0804622","volume":"360","author":"RM Scott","year":"2009","unstructured":"Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360:1226\u201337 (Massachusetts Medical Society).","journal-title":"N Engl J Med"},{"key":"1135_CR3","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3171\/2020.3.JNS192847","volume":"134","author":"TH Nielsen","year":"2021","unstructured":"Nielsen TH, Abhinav K, Sussman ES, Han SS, Weng Y, Bell-Stephens T, et al. Direct versus indirect bypass procedure for the treatment of ischemic moyamoya disease: results of an individualized selection strategy. J Neurosurg. 2021;134:1578\u201389.","journal-title":"J Neurosurg"},{"key":"1135_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1161\/STROKEAHA.113.004386","volume":"45","author":"S Miyamoto","year":"2014","unstructured":"Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke. 2014;45:1415\u201321.","journal-title":"Stroke"},{"key":"1135_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/neuros\/nyz074","volume":"86","author":"K Abhinav","year":"2020","unstructured":"Abhinav K, Furtado SV, Nielsen TH, Iyer A, Gooderham PA, Teo M, et al. Functional outcomes after revascularization procedures in patients with hemorrhagic moyamoya disease. Clin Neurosurg. 2020;86:257\u201365 (Oxford University Press).","journal-title":"Clin Neurosurg"},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2009.1.FOCUS08302","volume":"26","author":"AS Achrol","year":"2009","unstructured":"Achrol AS, Guzman R, Lee M, Steinberg KG. Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus. 2009;26:1\u20136 (American Association of Neurological Surgeons).","journal-title":"Neurosurg Focus"},{"key":"1135_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12975-021-00940-2","volume":"13","author":"R Mertens","year":"2022","unstructured":"Mertens R, Graupera M, Gerhardt H, Bersano A, Tournier-Lasserve E, Mensah MA, et al. The genetic basis of moyamoya disease. Transl Stroke Res. 2022;13:25\u201345.","journal-title":"Transl Stroke Res"},{"key":"1135_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/jhg.2010.132","volume":"56","author":"F Kamada","year":"2011","unstructured":"Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56:34\u201340.","journal-title":"J Hum Genet"},{"key":"1135_CR9","doi-asserted-by":"crossref","unstructured":"Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011;6(7):e22542.","DOI":"10.1371\/journal.pone.0022542"},{"key":"1135_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1534\/g3.115.020321","volume":"6","author":"LD Shoemaker","year":"2015","unstructured":"Shoemaker LD, Clark MJ, Patwardhan A, Chandratillake G, Garcia S, Chen R, et al. Disease variant landscape of a large multiethnic population of moyamoya patients by exome sequencing. G3 (Bethesda). 2015;6:41\u20139.","journal-title":"G3 (Bethesda)"},{"key":"1135_CR11","doi-asserted-by":"crossref","unstructured":"Xiao Y, Liu W, Hao J, Jiang Q, Wang X, Yu D, et al. CRISPR detection and research on screening mutant gene TTN of moyamoya disease family based on whole exome sequencing. Front Mol Biosci. 2022;9:846579.","DOI":"10.3389\/fmolb.2022.846579"},{"key":"1135_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jnnp.2009.191817","volume":"81","author":"HS Kang","year":"2010","unstructured":"Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81:673\u20138 (BMJ Publishing Group).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1135_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/092986732304160204181543","volume":"23","author":"G Bedini","year":"2016","unstructured":"Bedini G, Blecharz KG, Nava S, Vajkoczy P, Alessandri G, Ranieri M, et al. Vasculogenic and angiogenic pathways in moyamoya disease. Curr Med Chem. 2016;23:315\u201345 (Bentham Science Publishers Ltd).","journal-title":"Curr Med Chem"},{"key":"1135_CR14","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/01.STR.27.12.2160","volume":"27","author":"T Yoshimoto","year":"1996","unstructured":"Yoshimoto T, Houkin K, Takahashi A, Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996;27:2160\u20135 (Lippincott Williams and Wilkins).","journal-title":"Stroke"},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/01.STR.0000148237.13659.e6","volume":"35","author":"R Nanba","year":"2004","unstructured":"Nanba R, Kuroda S, Ishikawa T, Houkin K, Iwasaki Y. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke. 2004;35:2837\u201342.","journal-title":"Stroke"},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.surneu.2008.10.009","volume":"72","author":"M Fujimura","year":"2009","unstructured":"Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T. Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease. Surg Neurol. 2009;72:476\u201380.","journal-title":"Surg Neurol"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/foc.1998.5.5.5","volume":"5","author":"K Houkin","year":"1998","unstructured":"Houkin K, Yoshimoto T, Abe H, Nagashima K, Nagashima M, Takeda M, et al. Role of basic fibroblast growth factor in the pathogenesis of moyamoya disease. Neurosurg Focus. 1998;5:E4 (American Association of Neurological Surgeons).","journal-title":"Neurosurg Focus"},{"key":"1135_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/0304-3940(93)90416-I","volume":"160","author":"A Takahashi","year":"1993","unstructured":"Takahashi A, Sawamura Y, Houkin K, Kamiyama H, Abe H. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett. 1993;160:214\u20136 (Elsevier).","journal-title":"Neurosci Lett"},{"key":"1135_CR19","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1161\/01.STR.0000100159.43123.D7","volume":"34","author":"SK Kim","year":"2003","unstructured":"Kim SK, Yoo JIl, Cho BK, Hong SJ, Kim YK, Moon JA, et al. Elevation of CRABP-I in the cerebrospinal fluid of patients with moyamoya disease. Stroke. 2003;34:2835\u201341.","journal-title":"Stroke."},{"key":"1135_CR20","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.07.028","volume":"26","author":"D Kashiwazaki","year":"2017","unstructured":"Kashiwazaki D, Uchino H, Kuroda S. Downregulation of apolipoprotein-E and apolipoprotein-J in moyamoya disease\u2014a proteome analysis of cerebrospinal fluid. J Stroke Cerebrovasc Dis. 2017;26:2981\u20137 (W.B. Saunders).","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1135_CR21","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3174\/ajnr.A1538","volume":"30","author":"AS Vagal","year":"2009","unstructured":"Vagal AS, Leach JL, Fernandez-Ulloa M, Zuccarello M. The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia. Am J Neuroradiol. 2009;30:876\u201384 (American Journal of Neuroradiology).","journal-title":"Am J Neuroradiol"},{"key":"1135_CR22","first-page":"285","volume":"23","author":"JD Eastwood","year":"2002","unstructured":"Eastwood JD, Alexander MJ, Petrella JR, Provenzale JM. Dynamic CT perfusion imaging with acetazolamide challenge for the preprocedural evaluation of a patient with symptomatic middle cerebral artery occlusive disease. AJNR Am J Neuroradiol. 2002;23:285.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1135_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1227\/00006123-199209000-00003","volume":"31","author":"T Matsushima","year":"1992","unstructured":"Matsushima T, Inoue T, Suzuki SO, Fujii K, Fukui M, Hasuo K. Surgical treatment of moyamoya disease in pediatric patients\u2013comparison between the results of indirect and direct revascularization procedures. Neurosurgery. 1992;31:401\u20135.","journal-title":"Neurosurgery"},{"key":"1135_CR24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics"},{"key":"1135_CR25","doi-asserted-by":"crossref","unstructured":"Domagalski K, Paw\u0142owska M, Kozielewicz D, Dybowska D, Tretyn A, Halota W. The impact of IL28B genotype and liver fibrosis on the hepatic expression of IP10, IFI27, ISG15, and MX1 and their association with treatment outcomes in patients with chronic hepatitis C. PLoS One. 2015;10(6):e0130899.","DOI":"10.1371\/journal.pone.0130899"},{"key":"1135_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/01.RES.0000209968.66606.10","volume":"98","author":"RJ Bodnar","year":"2006","unstructured":"Bodnar RJ, Yates CC, Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res. 2006;98:617\u201325.","journal-title":"Circ Res"},{"key":"1135_CR27","doi-asserted-by":"crossref","unstructured":"Yates-Binder CC, Rodgers M, Jaynes J, Wells A, Bodnar RJ, Turner T. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. PLoS One. 2012;7(7):e40812.","DOI":"10.1371\/journal.pone.0040812"},{"key":"1135_CR28","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1242\/jcs.048793","volume":"122","author":"RJ Bodnar","year":"2009","unstructured":"Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A. IP-10 induces dissociation of newly formed blood vessels. J Cell Sci. 2009;122:2064\u201377.","journal-title":"J Cell Sci"},{"key":"1135_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5935\/0103-507X.20180003","volume":"30","author":"C Righy","year":"2018","unstructured":"Righy C, Turon R, De Freitas G, Japiass\u00fa AM, De Castro Faria Neto HC, Bozza M, et al. Hemoglobin metabolism by-products are associated with an inflammatory response in patients with hemorrhagic stroke. Rev Bras Ter Intensiva. 2018;30:21\u20137.","journal-title":"Rev Bras Ter Intensiva"},{"key":"1135_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jnnp.2009.191817","volume":"81","author":"HS Kang","year":"2010","unstructured":"Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81:673\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1135_CR31","doi-asserted-by":"crossref","unstructured":"Lange S, Heger J, Euler G, Wartenberg M, Piper HM, Sauer H. Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species. Cardiovasc Res. 2009;81(1):159\u201368.","DOI":"10.1093\/cvr\/cvn258"},{"key":"1135_CR32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1083\/jcb.125.4.917","volume":"125","author":"EJ Battegay","year":"1994","unstructured":"Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol. 1994;125:917 (The Rockefeller University Press).","journal-title":"J Cell Biol"},{"key":"1135_CR33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1161\/01.STR.29.6.1188","volume":"29","author":"M Yamamoto","year":"1998","unstructured":"Yamamoto M, Aoyagi M, Fukai N, Matsushima Y, Yamamoto K. Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke. 1998;29:1188\u201393.","journal-title":"Stroke"},{"key":"1135_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1476-5381.2011.01369.x","volume":"165","author":"MS Jamaluddin","year":"2012","unstructured":"Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165:622 (Wiley-Blackwell).","journal-title":"Br J Pharmacol"},{"key":"1135_CR35","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.3389\/fimmu.2021.747324","volume":"12","author":"D Chen","year":"2021","unstructured":"Chen D, Tang TX, Deng H, Yang XP, Tang ZH. Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. Front Immunol. 2021;12:5156 (Frontiers Media S.A.).","journal-title":"Front Immunol"},{"key":"1135_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jnnp.2009.191817","volume":"81","author":"HS Kang","year":"2010","unstructured":"Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81:673\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1135_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/362248a0","volume":"362","author":"A Minty","year":"1993","unstructured":"Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248\u201350.","journal-title":"Nature"},{"key":"1135_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","volume":"33","author":"H Yoshida","year":"2015","unstructured":"Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol. 2015;33:417\u201343.","journal-title":"Annu Rev Immunol"}],"updated-by":[{"DOI":"10.1007\/s12975-023-01149-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000}}],"container-title":["Translational Stroke Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-023-01135-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-023-01135-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-023-01135-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T03:30:33Z","timestamp":1708659033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12975-023-01135-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1007\/s12975-023-01135-7","relation":{},"ISSN":["1868-4483","1868-601X"],"issn-type":[{"value":"1868-4483","type":"print"},{"value":"1868-601X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12975-023-01149-1","URL":"https:\/\/doi.org\/10.1007\/s12975-023-01149-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. Dr. Steinberg is a consultant for SanBio, Zeiss, Peter Lazic, US, and Surgical Theater.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}